argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris
Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV).
Authors: Hübner F, Kasperkiewicz M, Zillikens D, Schmidt E Abstract Autoimmmune bullous diseases are mediated by pathogenetically relevant autoantibodies against components of the epidermis and/or superficial mucous membranes (in pemphigus) and structural proteins of the dermal-epidermal junction (in pemphigoid diseases). Using immunoadsorption (IA), an already well-established procedure in cardiac and rheumatic disorders, antibodies can be removed from the plasma. At present, most data on the adjuvant use of IA in dermatology are derived from patients with severe and/or refractory pemphigus vulgaris or pemphi...
PMID: 30537024 [PubMed - as supplied by publisher]
Abstract Cell-Cell contacts are crucial for intercellular cohesion and formation of endothelial and epithelial barriers. Desmosomes are the adhesive contacts providing mechanical strength to epithelial intercellular adhesion and therefore are most abundant in tissues subjected to high mechanical stress such as the epidermis and heart muscle. Desmogleins (Dsg) besides intercellular adhesion serve as signalling hubs regulating cell behaviour. In desmosomal diseases such as the autoimmune blistering skin disease pemphigus or arrhythmic cardiomyopathy (AC), which is caused by mutations of desmosomal components of card...
PMID: 30515763 [PubMed - as supplied by publisher]
Condition: Pemphigus Interventions: Drug: PRN1008 Oral Tablet; Drug: Placebo Oral Tablet Sponsor: Principia Biopharma, Inc. Recruiting
This study found a significantly increased zoster incidence in dermatomyositis and cutaneous lupus erythematosus compared with a control group.Physicians should be aware of this risk and consider administering the vaccine against zoster to these patients if not contraindicated.
•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other c ohorts.
AbstractDuring the last decade, successfully treatment of patients diagnosed with pemphigus vulgaris (PV) with rituximab (RTX) was reported by several authors. The present study has been designed to compare the clinical outcomes and RTX-related side effects between the two groups of early treated ( ≤ 6 months) and lately treated PV (> 6 months) patients with RTX. We did a retrospective study between Oct 2014 and Jun 2016 to compare the short-term efficacy and safety of RTX in PV diagnosed patients. The primary and secondary endpoints were complete/partial remission of disease and safely tapering of cor...
Contributors : Celine Derambure ; Fr éderique CaillotSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo understand the molecular and immunological mechanisms of remission in pemphigus patients. Remission was evaluated 5 years after rituximab onset. PBMC were purified from pemphigus whole blood patients. CD4+ T cells and CD19+ B cells were isolated by flow cytometry. Genes differentially regulated between CR and IR both in CD4+ and CD19+ cells were identified by transcriptomic approach (whole human genome).
We present the case of a 44-year-old woman with pemphigus vulgaris (PV) of 2 months’ duration. She presented to an emergency department (ED) for evaluation of her condition where she was diagnosed with acute necrotizing ulcerative gingivitis (ANUG).